Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Traditional drug-discovery model ripe for reform

Nature volume 471, pages 17–18 (2011)Cite this article

Subjects

A Correction to this article was published on 09 March 2011

Academic researchers set to play much greater role in pharmaceutical development.

With drug pipelines running dry and a slew of blockbuster medicines about to lose patent protection, the voices arguing that the traditional drug-development process is too expensive and inefficient to survive are getting louder.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Daniel Cressey
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

For a longer interview with Patrick Vallance, see go.nature.com/be99zf

Related links

Related links

Related links in Nature Research

Nature Reviews Drug Discovery

Related external links

Structural Genomics Consortium

Wellcome Trust Seeding Drug Discovery

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cressey, D. Traditional drug-discovery model ripe for reform. Nature 471, 17–18 (2011). https://doi.org/10.1038/471017a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/471017a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research